GlaxoSmithKline (GSK), Theravance (THRX) Announces US FDA Approval of … – StreetInsider.com

GlaxoSmithKline (GSK), Theravance (THRX) Announces US FDA Approval of
StreetInsider.com
GlaxoSmithKline (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) announced that the US Food and Drug Administration (FDA) has approved BREO ELLIPTA (fluticasone furoate/vilanterol [FF/VI]) for the once-daily treatment of asthma in patients aged 18 …
Glaxo Wins U.S. Approval to Sell Breo Only to Adults With AsthmaBloomberg
FDA approves Glaxo's inhaler drug Breo Ellipta for new use in treating adults Minneapolis Star Tribune

all 2 news articles »

View full post on asthma – Google News

GlaxoSmithKline grabs FDA approval for its latest asthma treatment – FierceBiotech


Bidness Etc

GlaxoSmithKline grabs FDA approval for its latest asthma treatment
FierceBiotech
"The approval of Arnuity Ellipta is an important development for GSK and our expanding respiratory portfolio," Senior Vice President Darrell Baker said in a statement. "It is the first asthma treatment from our new portfolio to have gained approval in
GSK's Asthma Treatment Gets FDA ApprovalBidness Etc
FDA OKs New Maintenance Asthma Treatment Arnuity ElliptaMedscape
FDA approves GSK asthma medicinePhiladelphia Business Journal (blog)
Healio –Monthly Prescribing Reference –The Pharma Letter
all 24 news articles »

View full post on asthma – Google News

GlaxoSmithKline Faces Criminal Investigation For Bribing Doctors In Poland To … – International Business Times


Livemint

GlaxoSmithKline Faces Criminal Investigation For Bribing Doctors In Poland To
International Business Times
UK-based drug maker, GlaxoSmithKline plc, or GSK, (LON:GSK) is facing a criminal investigation for bribing doctors in Poland to prescribe its asthma drug, Seretide, BBC reported Sunday. Must read. Google To Sell Glass To U.S. Customers April 15.
Drugs giant GSK accused of bribing doctors to prescribe its medicinesIrish Independent
GSK faces bribery investigation in Poland: reportLivemint

all 61 news articles »

View full post on asthma – Google News

GlaxoSmithKline Recalls Few Asthma Inhalers – TopNews United States


TopNews United States

GlaxoSmithKline Recalls Few Asthma Inhalers
TopNews United States
Thus, asthma sufferers are being reminded of the phenomenon "storm asthma" that starts with summer storms. Salbutamol, which is an active medication, is being doubted over its dose's full delivery. The medications are being expected to be delivered
Asthma sufferers urged to check inhalersNinemsn
Urgent recall of asthma inhalersSydney Morning Herald
Faulty asthma inhalers recalledYahoo!7 News
TopNews New Zealand –The Canberra Times
all 79 news articles »

View full post on asthma – Google News

GlaxoSmithKline initiates Phase III refractory asthma program – Equities.com

GlaxoSmithKline initiates Phase III refractory asthma program
Equities.com
The Phase III program includes two key studies: MEA115588: A 32-week multicenter, randomized, double-blind, double-dummy, placebo-controlled study in patients with severe uncontrolled refractory asthma. The primary endpoint of the study is to evaluate
Glaxo Starting Late-Stage Study of Asthma DrugPharmaceutical Processing
GlaxoSmithKline starts final-stage tests on severe asthma drugFox News
GSK takes severe asthma antibody into phase IIIPMLiVE
Zenopa –Fox Business –WHTC
all 25 news articles »

View full post on asthma – Google News

GlaxoSmithKline starts final-stage tests on severe asthma drug – Fox News

GlaxoSmithKline starts final-stage tests on severe asthma drug
Fox News
Severe refractory asthma only affects around 4 percent of patients with the disease, so the drug may not become a major seller for GSK but could consolidate the group's strong grip on the market for lung drugs. Print; Email; Share; Comments; Recommend
GSK Begins Phase lll Program for Mepolizumab in Severe Refractory AsthmaFox Business
GSK starts final-stage tests on severe asthma drugWHTC

all 14 news articles »

View full post on asthma – Google News

Drug Company GlaxoSmithKline Puts American Values to Shame – Huffington Post


The Guardian

Drug Company GlaxoSmithKline Puts American Values to Shame
Huffington Post
The asthma drug Advair became a never-ending blockbuster with sales of $7.8 billion in 2010 and predictions that the COPD drug market, which Advair leads, will reach $13.4 billion worldwide in 2020. The success is especially remarkable in regard to the
GlaxoSmithKline pays $3 billion in healthcare fraud settlementThe Depaulia
State receives $1.7M from largest health-care fraud settlement in US historyWyoming Business Report

all 58 news articles »

View full post on asthma – Google News

GlaxoSmithKline Boosts Stake In Theravance To 27% – RTT News


RTT News

GlaxoSmithKline Boosts Stake In Theravance To 27%
RTT News
The move is said to be on the potential success of asthma drug Relovair, which is believed to be the successor of Seretide/Advair that logged sales of roughly $8.1 billion in 2011. Relovair is developed by Theravance and GlaxoSmithKline and is a
GlaxoSmithKline to Increase Its Ownership in TheravanceMarketWatch (press release)
Glaxo Lifts Theravance StakeWall Street Journal
GlaxoSmithKline invests $213M in Theravance Inc.Triangle Business Journal
DailyFinance
all 48 news articles »

View full post on asthma – Google News